Why the study?
Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder with highly variable presentation and no pharmacologic therapies that alter its natural history.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Prioritizes symptom relief and SCD prevention in HCM; extends synthesis of options while leaving open prospective validation of emerging therapies.
Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining asymptomatic and others having significant limitation of functional status. The disorder is typically characterized by left ventricular hypertrophy that is not explained by another cause. Patients are further classified based on whether there is obstruction of the left ventricular outflow tract. To-date, there are no pharmacologic therapies that alter the natural history of the disease. Therapeutic approaches have instead focused on symptom relief and prevention of sudden cardiac death. Newer therapies under investigation represent potential means to improve limiting symptoms.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: